PT  - JOURNAL ARTICLE
AU  - Paranjpe, Ishan
AU  - Jayaraman, Pushkala
AU  - Su, Chen-Yang
AU  - Zhou, Sirui
AU  - Chen, Steven
AU  - Thompson, Ryan
AU  - Del Valle, Diane Marie
AU  - Kenigsberg, Ephraim
AU  - Zhao, Shan
AU  - Jaladanki, Suraj
AU  - Chaudhary, Kumardeep
AU  - Ascolillo, Steven
AU  - Vaid, Akhil
AU  - Kumar, Arvind
AU  - Kozlova, Edgar
AU  - Paranjpe, Manish
AU  - O’Hagan, Ross
AU  - Kamat, Samir
AU  - Gulamali, Faris F.
AU  - Kauffman, Justin
AU  - Xie, Hui
AU  - Harris, Joceyln
AU  - Patel, Manishkumar
AU  - Argueta, Kimberly
AU  - Batchelor, Craig
AU  - Nie, Kai
AU  - Dellepiane, Sergio
AU  - Scott, Leisha
AU  - Levin, Matthew A
AU  - He, John Cijiang
AU  - Suarez-Farinas, Mayte
AU  - Coca, Steven G
AU  - Chan, Lili
AU  - Azeloglu, Evren U
AU  - Schadt, Eric
AU  - Beckmann, Noam
AU  - Gnjatic, Sacha
AU  - Merad, Miram
AU  - Kim-Schulze, Seunghee
AU  - Richards, Brent
AU  - Glicksberg, Benjamin S
AU  - Charney, Alexander W
AU  - Nadkarni, Girish N
TI  - Proteomic Characterization of Acute Kidney Injury in Patients Hospitalized with SARS-CoV2 Infection
AID  - 10.1101/2021.12.09.21267548
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2021.12.09.21267548
4099  - http://medrxiv.org/content/early/2022/08/29/2021.12.09.21267548.short
4100  - http://medrxiv.org/content/early/2022/08/29/2021.12.09.21267548.full
AB  - Acute kidney injury (AKI) is a known complication of COVID-19 and is associated with an increased risk of in-hospital mortality. Unbiased proteomics using biological specimens can lead to improved risk stratification and discover pathophysiological mechanisms. Using measurements of ∼4000 plasma proteins in two cohorts of patients hospitalized with COVID-19, we discovered and validated markers of COVID-associated AKI (stage 2 or 3) and long-term kidney dysfunction. In the discovery cohort (N= 437), we identified 413 higher plasma abundances of protein targets and 40 lower plasma abundances of protein targets associated with COVID-AKI (adjusted p <0.05). Of these, 62 proteins were validated in an external cohort (p <0.05, N =261). We demonstrate that COVID-AKI is associated with increased markers of tubular injury (NGAL) and myocardial injury. Using estimated glomerular filtration (eGFR) measurements taken after discharge, we also find that 25 of the 62 AKI-associated proteins are significantly associated with decreased post-discharge eGFR (adjusted p <0.05). Proteins most strongly associated with decreased post-discharge eGFR included desmocollin-2, trefoil factor 3, transmembrane emp24 domain-containing protein 10, and cystatin-C indicating tubular dysfunction and injury. Using clinical and proteomic data, our results suggest that while both acute and long-term COVID-associated kidney dysfunction are associated with markers of tubular dysfunction, AKI is driven by a largely multifactorial process involving hemodynamic instability and myocardial damage.Competing Interest StatementGNN and SGC reports grants, personal fees, and non-financial support from Renalytix. GNN reports non-financial support from Pensieve Health, personal fees from AstraZeneca, personal fees from BioVie, personal fees from GLG Consulting, personal fees from Siemens Healthineers from outside the submitted work. IP receives personal fees from Character Biosciences.Funding StatementEUA, GNN, JCH and SGC are partially funded by R01 DK118222. GNN also is supported by R01DK127139, R01HL155915 and R56DK126930.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Icahn School of Medicine Mt. Sinai gave ethical approval for this work using STUDY-20-00338I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available by contacting the senior author, Girish Nadkarni (girish.nadkarni@mountsinai.org). Code is available at https://github.com/Nadkarni-Lab/aki_covid_proteomics